ANAB ANAPTYSBIO, INC
Price Chart
Executive Summary
Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 notice of intent to sell 35,000 common shares valued at approximately $1.85 million, to be executed through Morgan Stanley. The filing also reveals a heavy pattern of insider selling: Mulroy has sold over 260,000 shares in the past three weeks (May 15–June 10), totaling about $13.4 million, all via open-market sales after stock option exercises. This sustained selling by a top officer ahead of any public catalyst is a significant bearish signal.
Actionable Insight
The sustained insider selling by a top officer at a rate of ~$1M/week is a strong negative signal, especially given the stock's high valuation and bullish analyst consensus. Traders should consider reducing exposure or hedging ahead of potential negative catalysts (e.g., clinical data, earnings). Monitor for Form 4 filings to confirm actual sales and watch for any material news that could explain the selling.
Key Facts
- Officer Dennis Mulroy filed Form 144 to sell 35,000 shares (~$1.85M) on June 11, 2026.
- The filing reveals 18 prior open-market sales between May 15 and June 10, 2026, totaling ~260,000 shares and ~$13.4M.
- All sales were executed after stock option exercises, indicating a systematic plan to monetize equity.
- AnaptysBio has a $1.5B market cap and 94% analyst bullish consensus, making the insider selling pattern particularly notable.
- Historical calibration shows score-6 filings in this segment have a 34% observed probability of up-move at T+20, with a net negative average alpha.
Financial Impact
Officer sold ~$13.4M in shares over 3 weeks, with an additional $1.85M proposed; total ~$15.3M in planned sales.
Risk Factors
- Insider selling may indicate undisclosed negative developments (e.g., clinical trial setbacks, regulatory delays).
- Heavy option exercise and sale pattern could pressure the stock if selling continues.
- The 144 filing is an intent to sell; if the insider does not execute, the signal may be less severe.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-005960 |
| Document: 0001950047-26-005960-index.html | 0001950047-26-005960 |
| Document: 0001950047-26-005960.txt | 0001950047-26-005960 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 15, 2026
1d ago
|
144
| $59.48 awaiting T+1 | awaiting T+1 | — | $57.61 (+3.14%) |
|
Jun 11, 2026
5d ago
|
144
| $56.07 $59.51 | ▼ −6.14% | ▼ −4.37% | $57.61 (−2.75%) |
|
Jun 10, 2026
6d ago
|
144
| $54.24 $56.07 | ▼ −3.37% | ▼ −2.83% | $57.61 (−6.21%) |
|
Jun 8, 2026
8d ago
|
144
| $51.63 $52.10 | ▼ −0.91% | ▼ −2.49% | $57.61 (−11.58%) |
|
Jun 5, 2026
11d ago
|
144
| $51.36 $51.63 | ▼ −0.53% | ▼ −0.82% | $57.61 (−12.17%) |
|
Jun 5, 2026
11d ago
|
144
| $50.37 $51.36 | ▼ −1.97% | ▼ −1.74% | $57.61 (−14.37%) |
|
Jun 3, 2026
13d ago
|
144
| $51.67 $50.37 | ▲ +2.52% | ▼ −0.08% | $57.61 (−11.50%) |
|
Jun 1, 2026
15d ago
|
144
| $51.26 $51.24 | ▲ +0.04% | ▼ −0.68% | $57.61 (−12.39%) |
|
May 29, 2026
18d ago
|
8-K
| $53.14 $51.26 | ▼ −3.54% | ▼ −3.69% | $57.61 (+8.41%) |
|
May 28, 2026
19d ago
|
144
| $55.67 $53.14 | ▼ −4.54% | ▼ −4.80% | $57.61 (+3.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access